Tharimmune, Inc.
1D
1W
1M
3M
YTD
1Y
5Y
ALL
Why Robinhood?
Robinhood gives you the tools you need to put your money in motion. You can buy or sell THAR and other ETFs, options, and stocks.About THAR
Tharimmune, Inc. is a clinical-stage biotechnology company developing a portfolio of therapeutic candidates for inflammation and immunology. It also develops TH104, which is known to suppress chronic, debilitating pruritus or "uncontrollable itching" in PBC, a rare and orphan liver disease with no known cure.
CEOMark Wendland
CEOMark Wendland
Employees2
Employees2
HeadquartersBridgewater, New Jersey
HeadquartersBridgewater, New Jersey
Founded2017
Founded2017
Employees2
Employees2
THAR Key Statistics
Market cap82.60M
Market cap82.60M
Price-Earnings ratio-0.62
Price-Earnings ratio-0.62
Dividend yield—
Dividend yield—
Average volume267.91K
Average volume267.91K
High today$2.42
High today$2.42
Low today$2.32
Low today$2.32
Open price$2.38
Open price$2.38
Volume715.23K
Volume715.23K
52 Week high$9.08
52 Week high$9.08
52 Week low$0.952
52 Week low$0.952
Stock Snapshot
Tharimmune, Inc.(THAR) stock is priced at $2.36, giving the company a market capitalization of 82.6M. It carries a P/E multiple of -0.62.
On 2025-12-17, Tharimmune, Inc.(THAR) stock traded between a low of $2.32 and a high of $2.42. Shares are currently priced at $2.36, which is +1.7% above the low and -2.5% below the high.
The Tharimmune, Inc.(THAR)'s current trading volume is 715.23K, compared to an average daily volume of 267.91K.
In the last year, Tharimmune, Inc.(THAR) shares hit a 52-week high of $9.08 and a 52-week low of $0.95.
In the last year, Tharimmune, Inc.(THAR) shares hit a 52-week high of $9.08 and a 52-week low of $0.95.
People also own
Based on the portfolios of people who own THAR. This list is generated using Robinhood data, and it’s not a recommendation.